A Phase 2a, Safety, Tolerability, Pharmacokinetics and Quantitative EEG Study of CX-8998 in Adolescents and Young Adults With Generalized Epileptic Syndromes With Absence Seizures

Trial Profile

A Phase 2a, Safety, Tolerability, Pharmacokinetics and Quantitative EEG Study of CX-8998 in Adolescents and Young Adults With Generalized Epileptic Syndromes With Absence Seizures

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs CX 8998 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms T-WAVE
  • Sponsors Cavion
  • Most Recent Events

    • 20 Mar 2018 According to a Cavion media release, the first patient has been enrolled in this trial.
    • 25 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top